Tempus Ai, Inc. Class A Common Stock

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

Tempus to Report First Quarter 2026 Financial Results on May 5

Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring

Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026

Tempus Launches Automated “Active Follow-Up” Service to Support Guideline-Concordant Care